Cicchetti (Altems): “New therapy for haemophilia A has no impact on NHS”
"Ephmoroctocog alfa (Elocta *), the first recombinant factor VIII with a prolonged half-life for haemophilia A, is an innovative therapy ...
"Ephmoroctocog alfa (Elocta *), the first recombinant factor VIII with a prolonged half-life for haemophilia A, is an innovative therapy ...
“Unlike what happens in the rest of the world, artificial crystallines are not inserted in Italian hospitals, like those I ...
"Every year 7 thousand Italian ophthalmologists visit 20 million patients, perform 1 million sight-saving surgeries and undertake to deliver 1 ...
"The growing involvement of citizens and patient associations by public decision makers in defining the most relevant choices for healthcare ...
(Adnkronos) - "Since the pandemic broke out, we have been working every day to ensure that no citizen is left ...